{
    "clinical_study": {
        "@rank": "95625", 
        "arm_group": [
            {
                "arm_group_label": "Verapamil", 
                "arm_group_type": "Active Comparator", 
                "description": "Verapamil 2.5 mg/mL injection sc intralesionally"
            }, 
            {
                "arm_group_label": "Kenalog 10", 
                "arm_group_type": "Active Comparator", 
                "description": "Kenalog 10 mg/mL injection sc intralesionally"
            }
        ], 
        "brief_summary": {
            "textblock": "Keloid scarring is a severe cosmetic and painful disease of the skin. The gold standard\n      treatment is yet to be clarified. This randomized clinical pilot study will compare the\n      effects of two local treatments for preventing keloid recurrence after surgical removal;\n      steroid and verapamil.\n\n      Study hypothesis: Intralesional therapy with the calcium antagonist verapamil has equal\n      treatment efficacy as steroid injection."
        }, 
        "brief_title": "Verapamil vs Steroid to Prevent Keloid Recurrence", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Keloid Scars", 
        "condition_browse": {
            "mesh_term": [
                "Keloid", 
                "Recurrence", 
                "Cicatrix"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient undergoing surgical removal of keloid\n\n          -  Patient 18 years old or greater\n\n          -  Length of excisional scar after surgical removal of keloid between 2 and 10 cm\n\n        Exclusion Criteria:\n\n          -  Keloid in face or hands\n\n          -  Pregnancy or lactation\n\n          -  Dementia\n\n          -  Any heart or pulmonary condition\n\n          -  Systemic treatment with beta-blockers, ACE-inhibitors or calcium antagonists\n\n          -  Systemic corticosteroidal therapy\n\n          -  Intralesional steroid treatment within 2 months of surgery to remove keloid\n\n          -  Flap surgery\n\n          -  Lesions to face, hands and other cosmetically sensitive areas"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01720056", 
            "org_study_id": "EC 067/2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "Verapamil", 
                "intervention_name": "Verapamil", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Kenalog 10", 
                "intervention_name": "Kenalog 10", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Verapamil", 
                "Triamcinolone hexacetonide", 
                "Triamcinolone", 
                "Triamcinolone Acetonide", 
                "Triamcinolone diacetate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 30, 2012", 
        "location": {
            "contact": {
                "last_name": "Fiona M Wood, Professor"
            }, 
            "facility": {
                "address": {
                    "city": "Perth", 
                    "country": "Australia", 
                    "state": "Western Australia", 
                    "zip": "6001"
                }, 
                "name": "Royal Perth Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Patricia L. Danielsen, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Hilary Wallace, Dr.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Suzanne Rea, Professor", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "2", 
        "official_title": "Assessment of Verapamil as an Adjunct for Prevention of Keloid Recurrence After Surgical Removal", 
        "overall_contact": {
            "email": "patriciadanielsen@yahoo.dk", 
            "last_name": "Patricia L. Danielsen, MD, PhD", 
            "phone": "0448697737"
        }, 
        "overall_contact_backup": {
            "email": "hilary.wallace@uwa.edu.au", 
            "last_name": "Hilary Wallace, Dr."
        }, 
        "overall_official": {
            "affiliation": "The University of Western Australia", 
            "last_name": "Fiona M Wood, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Australia: Human Research Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Keloid recurrence", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01720056"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The University of Western Australia", 
            "investigator_full_name": "Fiona M. Wood", 
            "investigator_title": "Prof. Wood", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Vancouver Scar Scale Score", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "source": "The University of Western Australia", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The University of Western Australia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}